Daniel Virnich, Chief Executive Officer of Starling Oncology, Inc. (NASDAQ:STLN), filed a Form 4 on November 19, 2026, disclosing a disposition of 5,102 shares of common stock on November 17, 2026, in connection with the vesting of restricted stock units.
Key Highlights
- Reporting person: Daniel Virnich, Chief Executive Officer of Starling Oncology, Inc.
- Transaction date: November 17, 2026, coded as transaction type "J" in the filing.
- Shares disposed: 5,102 shares of common stock at a price of $3.4 per share.
- Post-transaction ownership: Virnich directly owned 2,332,064 shares following the reported transaction.
- Nature of transaction: The filing states the shares were "required to be sold pursuant to a sell-to-cover transaction in satisfaction of tax withholding obligations in connection with the vesting of restricted stock units, mandated by the Issuer and does not reflect a discretionary trade by the Reporting Person."
- Filing signed by: Mark Hueppelsheuser, Attorney-in-Fact for Daniel Virnich, on November 19, 2026.
Starling Oncology CEO Virnich: RSU Vest Triggers Mandatory Share Sale
According to the Form 4 filed with the U.S. Securities and Exchange Commission, Daniel Virnich, the Chief Executive Officer of Starling Oncology, Inc., disposed of 5,102 shares of the company's common stock on November 17, 2026. The transaction was recorded under transaction code "J" and carried a price of $3.4 per share. The filing identifies Starling Oncology, Inc. as the issuer, trading on NASDAQ under the symbol STLN.
The filing's explanation of responses states that the sale reflects shares "required to be sold pursuant to a sell-to-cover transaction in satisfaction of tax withholding obligations in connection with the vesting of restricted stock units, mandated by the Issuer." The filing explicitly notes the transaction "does not reflect a discretionary trade by the Reporting Person." Following the disposition, Virnich's direct beneficial ownership in Starling Oncology common stock stood at 2,332,064 shares, according to the filing.
The Form 4 was submitted as an individual filing by one reporting person and was signed on November 19, 2026, by Mark Hueppelsheuser, acting as Attorney-in-Fact for Daniel Virnich. No derivative securities transactions were reported in Table II of the filing.
What Was Disclosed
Starling Oncology CEO Daniel Virnich filed a Form 4 disclosing a mandatory sell-to-cover disposition of 5,102 common shares at $3.4 per share on November 17, 2026, tied to RSU vesting tax obligations, leaving him with direct ownership of 2,332,064 shares.



Please wait processing your request...